Paul Brady Photography / Shutterstock.com
15 November 2022AmericasStaff Writer
FTC wades into escalating ‘Orange Book’ clash
Jazz accused a rival of infringement | Avadel filed a counterclaim seeking to delist the patent from the Orange Book.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
16 November 2021 Jazz Pharmaceuticals has claimed that Avadel Pharmaceuticals’ proposed narcolepsy drug infringes a patent related to Jazz’s blockbuster treatment Xyrem.
Americas
22 December 2022 Delisting affects a blockbuster narcolepsy drug | Orange book has specific listing criteria | Avadel.
Editor's picks
Editor's picks
Americas
16 November 2021 Jazz Pharmaceuticals has claimed that Avadel Pharmaceuticals’ proposed narcolepsy drug infringes a patent related to Jazz’s blockbuster treatment Xyrem.
Americas
22 December 2022 Delisting affects a blockbuster narcolepsy drug | Orange book has specific listing criteria | Avadel.
Americas
16 November 2021 Jazz Pharmaceuticals has claimed that Avadel Pharmaceuticals’ proposed narcolepsy drug infringes a patent related to Jazz’s blockbuster treatment Xyrem.
Americas
22 December 2022 Delisting affects a blockbuster narcolepsy drug | Orange book has specific listing criteria | Avadel.